[go: up one dir, main page]

WO2024214120A1 - Composition pharmaceutique du nilotinib - Google Patents

Composition pharmaceutique du nilotinib Download PDF

Info

Publication number
WO2024214120A1
WO2024214120A1 PCT/IN2024/050382 IN2024050382W WO2024214120A1 WO 2024214120 A1 WO2024214120 A1 WO 2024214120A1 IN 2024050382 W IN2024050382 W IN 2024050382W WO 2024214120 A1 WO2024214120 A1 WO 2024214120A1
Authority
WO
WIPO (PCT)
Prior art keywords
nilotinib
pharmaceutical composition
immediate release
release pharmaceutical
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/IN2024/050382
Other languages
English (en)
Inventor
Eslavath PURAMDAS
Singh Sanjay Kumar
Chaudhari Sangmesh MALLIKARJUN
Choudhury Anup AVIJIT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Reddys Laboratories Ltd
Original Assignee
Dr Reddys Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Reddys Laboratories Ltd filed Critical Dr Reddys Laboratories Ltd
Publication of WO2024214120A1 publication Critical patent/WO2024214120A1/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Definitions

  • the present invention relates to immediate release pharmaceutical composition
  • immediate release pharmaceutical composition comprising amorphous solid dispersions of the protein kinase inhibitor or a pharmaceutically acceptable salt thereof. More particularly, the present invention relates to immediate release pharmaceutical compositions of nilotinib, or a pharmaceutically acceptable salt thereof. A method of preparation of the said compositions is also dislcosed.
  • Nilotinib is a kinase inhibitor having the following structure:
  • Nilotinib is 4-methyl-N-[3-(4-methyl-lH-imidazol-l-yl)-5- ( trifluoromethyl )phenyl] -3- [ [4 - ( 3 -pyridinyl)-2-pyrimidinyl] amino] -benzamide.
  • the molecular formula is C28H22F3N7O, which corresponds to a molecular weight of 529 g/mol (nilotinib base, anhydrous).
  • Nilotinib is marketed under the tradename TASIGNA®, as an immediate- release formulation containing nilotinib monohydrochloride monohydrate and is used to treat certain types of chronic myeloid leukemia.
  • Nilotinib monohydrochloride monohydrate is characterized as a Class IV compound (low/moderate aqueous solubility and low permeability) according to the Biopharmaceutical Classification System (“BCS”).
  • BCS Biopharmaceutical Classification System
  • the solubility of Nilotinib in aqueous solutions decreases with increasing pH.
  • the recommended dosage of TASIGNA® is 300mg or 400mg orally twice daily. Based on the reported data, the absorption of Nilotinib after oral administration of TASIGNA® is approximately 30%. When TASIGNA® is administered with high fat meal, maximum concentration (Cmax) and area under the curve (AUC) increases 112% and 82%, respectively.
  • Cmax maximum concentration
  • AUC area under the curve
  • Such an increase in serum levels may also exacerbate or increase the prevalence of common side effects such as nausea, diarrhea, rash, headache, muscle and joint pain, tiredness, vomiting, and fever; as well as more serious side effects such as low blood cell counts, decreased blood flow to the heart or brain, pancreas inflammation, liver problems, and bleeding problems.
  • nilotinib significantly decreases with increasing pH, and therefore nilotinib absorption may be compromised if TASIGNA® is administered along with gastric acidreducing agents.
  • Use of TASIGNA® with common gastric acid-reducing agents is restricted in accordance with prescribing information.
  • WO2013105894A1 provides an amorphous hybrid nanoparticle formulation produced by using Nilotinib or pharmaceutically acceptable salt thereof and a polymeric stabilizing and matrix-forming component.
  • the method used in this disclosure, for the preparation of amorphous hydrid nanoparticle is supercritical fluid technology.
  • WO2021222739 Al provides pharmaceutical composition in the form of orally disintegrating tablet and comprises of an amorphous solid dispersion of nilotinib orally disintegrating formulations are the formulations which rapidly disintegrates or dissolves in the oral cavity without using water and mainly targeted for geriatric patient polulations.
  • US20150273070A1 discloses nilotinib solubilized modified release solid dosage forms containing organic acids.
  • an immediate release formulation comprising amorphous solid dispersion (ASD) of nilotinib or it’s pharmaceutically acceptable salts and a polymer wherein the said polymer has a high glass transition temperature.
  • ASD amorphous solid dispersion
  • the polmyers having glass transition temperature of more than 100 ° C are preferred.
  • an immediate release formulation comprising amorphous solid dispersion of nilotinib or it’s pharmaceutically acceptable salts and a polymer having high glass transition temperature and one or more excipinets.
  • the pharmaceutically acceptable excipient are selected from at least one filler, and/or at least one binder and/or at least one disintegrant, and/or at least one glidant, and/or at least one lubricant and at least one solublizer.
  • the present immediate release formulation provides improved solubility and abosprtion of nilotinib.
  • the absorption of nilotinib from the present composition is minimally dependent on the food intake and thus, in preferred embodiment of the present invention, the immediate release tablet for the present invention can be administered independent of the food consumption.
  • the present immediate release formulation provides unusually large enhancements in aqueous concentration in an environment of use and theraby improvement in the oral bioavalability and thus possibility of administering a reduced dose to achieve a similar effect which is achieved by currently marketed TASIGNA® formulation.
  • Yet another aspect of the disclosure relates to a method of increasing bioavailability of nilotinib in a human subject, wherein the method comprises administration of a pharmaceutical composition comprising an amorphous solid dispersion (“ASD”) of nilotinib to the human subject, and wherein the bioavailability is increased by least 1.3 fold, preferably at least 1.5 fold, and more preferably by at least 2 fold, as compared to reference immediate-release crystalline nilotinib capsule TASIGNA®.
  • ASSD amorphous solid dispersion
  • the pharmaceutical compositions of the present disclosure unexpectedly provide a pharmacokinetic profile similar to that of TASIGNA® , even when the dose of nilotinib administered by the pharmaceutical compositions is a fraction of the dose of nilotinib normally administered when using TASIGNA®. Therefore, the disclosure provides pharmaceutical compositions that can be administered at a lower dose than TASIGNA®, but is bioequivalent to TASIGNA® and thus would be expected to provide a comparable therapeutic effect.
  • Yet another aspect of the disclosure relates to a method of preparation of immediate release pharmaceutical composition
  • a method of preparation of immediate release pharmaceutical composition comprising an amorphous solid dispersion comprising nilotinib by solvent controlled precipitation technique using a suitable polymer having a high glass transition temperature (more than 100 ° C).
  • the disclosure provides a method of manufacturing amorphous solid dispersions nilotinib, wherein the method comprises: (i) preparing a solution comprising nilotinib and one or more polymers, and (ii) mixing the solutions with at least one anti-solvent to obtain a suspension of amorphous particles by co-precipitation.
  • Yet another aspect of the disclosure relates to a method of treating a disease which responds to an inhibition of protein kinase activity, such as a proliferative disorder.
  • the present disclosure relates to a method of treating a proliferative disorder in a patient in need thereof, the method comprising administering a therapeutically effective amount of a pharmaceutical composition of the present disclosure to the patient without regard to consumption of food.
  • the present disclosure relates to a method of treating a proliferative disorder in a patient in need thereof, the method comprising administration of an ASD or pharmaceutical composition of the present disclosure to a patient without regard to whether the patient is in a fasted state or a fed state.
  • Figure 1 XRD diffractogram of Nilotinb amorphous solid dispersion.
  • the present invention relates to immediate release pharmaceutical composition comprising amorphous solid dispersion (“ASD”) of nilotinib that provide particular advantages, and offer a safer but equally effective composition of nilotinib as compared to the currently available conventional immediate-release nilotinib formulations, such as TASIGNA®.
  • ASD amorphous solid dispersion
  • amorphous solid dispersion refers to dispersion of at least one drug in a matrix, in the amorphous state.
  • the matrix may comprise polymers, optionally solubilizer or mixtures thereof.
  • 'nilotinib' used herein refers broadly to nilotinib free base, salts of nilotinib, anhydrous nilotinib (or salts thereof), hydrates or solvates of nilotinib, and hydrates or solvates of nilotinib salts as suitable alternatives, unless specified.
  • TASIGNA® refers to commercially available TASIGNA® immediate -release capsules, available in strengths of 50mg, 150mg and 200mg, marketed by Novartis.
  • immediate-release refers to the rapid release of the majority of the therapeutic compound, e.g., greater than about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, or about 90% within a relatively short time, e.g., within 1 hour, 40 minutes, 30 minutes or 20 minutes after oral ingestion.
  • Particularly useful conditions for immediate -release are release of at least or equal to about 80% of the therapeutic compound within forty-five minutes after oral ingestion.
  • the particular immediate -release conditions for a specific therapeutic compound will be recognized or known by one of ordinary skill in the art.
  • composition means solid oral form i.e., either a tablet or capsules or granules, more preferably the solid dosage form is present in the form of tablets, suitable for oral administration.
  • An object of the present invention is to provide an immediate release pharmaceutical composition comprising amorphous solid dispersion comprising nilotinib.
  • the ASD comprises nilotinib and one or more suitable polymers and optionally a solubilizer.
  • the polymer employed in preparation of ASD has a high glass transition temperature, preferably more than 75°C, more preferably more than 100 ° C.
  • Glass transition temperature (Tg) as used herein is the characteristic temperature where a glassy material, upon gradual heating, undergoes a relatively rapid (e.g., 10 to 100 seconds) physical change from a glass state to a rubber state.
  • the present invention provides an amorphous solid dispersion of nilotinib with a suitable polymer having a glass transition point in the range of from 100 °C to 180 °C; preferably from 110 °C to 160 °C.
  • the glass transition temperature may be measured by Heat Flux Differential Scanning calorimetry or Power Compensation Differential Scanning calorimetry.
  • the suitable polymer having a glass transition temperature of from 110 °C to 160 °C is selected from the group consisting of Cellulose acetate phthalate, Polyvinyl acetate phthalate, Eudragit L100-55, modified HPMCs, such as hydroxypropyl methylcellulose acetatesuccinate (HPMC-AS) and hydroxypropyl methylcellulose phthalate (HPMCP), or mixtures thereof.
  • the nilotinib : polymer ratio is in the range of 1: 0.5 to 1: 5, preferably 1: 1 to 1: 3 and more preferably from 1:1 to 1:2.
  • the present specification further discloses a process wherein co-precipitated particles of nilotinib and polymer are obtained through solvent controlled precipitation, a technique in which a drug and polymer are dissolved in a solvent, and this solution is then added to an antisolvent. The drug and polymer then precipitate out simultaneously in the antisolvent.
  • a method of manufacturing amorphous solid dispersions nilotinib comprising: (i) preparing a solution comprising nilotinib and a solution comprising one or more polymers, a stabilizing agents, wherein each solution is prepared using a first solvent, and (ii) mixing the solutions with a second solvent which comprises at least one anti-solvent to obtain a suspension of amorphous particles by coprecipitation.
  • the solution comprising the pharmaceutically active compound and the solution comprising at least one polymer are combined to form a first stream, prior to mixing with the second solvent, an anti-solvent of both the pharmaceutically active ingredient and the polymer.
  • the first stream solution comprising the polymer and active compound is combined with the second solvent to form a second stream, which second stream comprises an anti-solvent of the pharmaceutically active compound.
  • solvent is used herein to describe a solvent or a mixture of solvents, which is any substance, usually liquid, which is capable of dissolving nilotinib or it’s salt and the polymer. .
  • the first and/or the second solvent is selected from: water, acetone, methylchloride, dimethylformamide, methanol, ethanoldimethyl sulfoxide, methylethylketone, dimethylacetamide, lactic acid, isopropanol, 3-pentanol, n-propanol, glycerol, butylene glycol, ethylene glycol, propylene glycol, dimethyl isosorbide, tetrahydrofuran, 1 ,4-dioxanepolyethylene glycol, polyethylene glycol esters, polyethylene glycol sorbitans, polyethylene glycol monoalkyl ethers, polypropylene glycol, polypropylene alginate, butanediol, and mixtures thereof.
  • anti-solvent is used herein to describe a solvent, which is any substance, usually liquid, and has a very poor solublity for nilotinib and pharmaceutically acceptable salt.
  • solution containing Nilotinib or pharmaceutically acceptable salt is mixed with the common anti-solvent, the Nilotinib or pharmaceutically acceptable salt precipitate within the anti-solvent as opposed to dissolving within in, preferably forming composite particles made of the different substances.
  • the anti-solvent is preferably acidified water with a pH 1.0-5.0.
  • the anti-solvent may be miscible or immiscible with the solvent and has low solubility for Nilotinib.
  • the preferred anti-solvent is, but not exclusively, an aqueous solution which may be provided with one or more surface modifiers such as an anionic surfactant, a cationic surfactant or a nonionic surfactant mixed in it.
  • the aqueous solution comprises deionized water.
  • an amorphous solid dispersion of Nilotinib is manufactured by a method comprising: (i) preparing a solution comprising nilotinib and one or more suitable polymers having a high glass transition temperature using dimethylacetamide as the solvent; (i) mixing the solution obtained in step (i) to cooled acidified water (pH 1-5) to precipitate out both the drug and the polymer; (iii) filtering and washing the solid mass obtained in step (ii) with fresh antisolvent and water, and dried to obtain amorphous solid dispersion of the present invention.
  • Another object of the present invention is to provide pharmaceutical compositions comprising the ASDs.
  • the present invention provides a pharmaceutical composition comprising an ASD of nilotinib and and one or more solubilizers.
  • Solubilizers that may be used in the pharmaceutical compositions of the present disclosure include, but are not limited to, polyvinyl caprolactam-polyvinyl acetate -polyethylene glycol copolymer (SOLUPLUS), d-D-tocopherol acid polyethylene glycol (PEG) 1000 succinate (TPGS), PEG-40 hydrogenated castor oil (CREMOPHOR RH40), PEG-35 castor oil (CREMOPHOR EL), PEG-40 stearate (MYRJ 540), hard fat (such as GELUCIRE 33/01), polyoxylglycerides (such as GELUCIRE 44/14), stearoyl polyoxylglycerides (such as GELUCIRE 50/13), PEG-8 caprylic/capric gly
  • compositions in the form of solid oral dosage forms may also include other pharmaceutically acceptable excipient(s) selected from a group, comprising one or more fillers, one or more binders, one or more lubricants, one or more disintegrants, and/or other conventional excipients such as one or more glidants, one or more buffering agent(s), one or more pH-adjusting agents, one or more surfactants, one or more antioxidants, one or more precipitation-inhibitors and/or one or more carriers, for example.
  • excipient(s) selected from a group, comprising one or more fillers, one or more binders, one or more lubricants, one or more disintegrants, and/or other conventional excipients such as one or more glidants, one or more buffering agent(s), one or more pH-adjusting agents, one or more surfactants, one or more antioxidants, one or more precipitation-inhibitors and/or one or more carriers, for example.
  • Suitable fillers include acacia, calcium carbonate, calcium sulfate, calcium sulfate dihydrate, compressible sugar, dibasic calcium phosphate anhydrous (e.g., FUJICALIN, EMCOMPRESS), dibasic calcium phosphate dihydrate, tribasic calcium phosphate, monobasic sodium phosphate, dibasic sodium phosphate, lactose monohydrate, lactose anhydrous, magnesium oxide, magnesium carbonate, silicon dioxide, magnesium aluminum silicate, maltodextrin, mannitol, methyl cellulose, microcrystalline cellulose (e.g., AVICEL PH-101, AVICEL PH-102), powdered cellulose, starches, sorbitol, dextrose, dextrates, dextrin, sucrose, xylitol and mixtures thereof.
  • dibasic calcium phosphate anhydrous e.g., FUJICALIN, EMCOMPRESS
  • Suitable binders include various celluloses (e.g. HPMC, HPC, starch, ect.), povidone, cross-linked polyvinylpyrrolidone, microcrystalline cellulose (e.g., AVICEL PH-101, AVICEL PH-102, AVICEL PH-105), or silicified microcrystalline cellulose (e.g., PROSOLV SMCC), for example.
  • celluloses e.g. HPMC, HPC, starch, ect.
  • povidone e.g., cross-linked polyvinylpyrrolidone
  • microcrystalline cellulose e.g., AVICEL PH-101, AVICEL PH-102, AVICEL PH-105
  • silicified microcrystalline cellulose e.g., PROSOLV SMCC
  • One or more lubricants may be included to reduce friction with and adherence to processing equipment during processing.
  • suitable lubricants include, but are not limited to, magnesium stearate, calcium stearate, zinc stearate, stearic acid, stearyl alcohol, glyceryl monostearate, sodium stearyl fumarate, talc, glyceryl behenate, sodium benzoate, sodium lauryl sulfate, and the like.
  • the one or more lubricant is generally present in the range of 0.1% to 5%, by weight of the pharmaceutical composition. In some embodiments, the one or more lubricant is generally present in the range of 0.25% to 2%, by weight of the pharmaceutical composition. In certain embodiments, the lubricant is magnesium stearate.
  • Suitable disintegrants in the practice of the disclosure include natural, modified or pre- gelatinized starch, sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpolypyrrolidone (“PVPP”), and mixtures thereof.
  • natural, modified or pre- gelatinized starch sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpolypyrrolidone (“PVPP”), and mixtures thereof.
  • Glidants are employed to improve flow properties of a powder or granule mixture prior to further processing (such as tablet compression, for example).
  • Suitable glidants that may be employed in the compositions of the present disclosure include, but are not limited to, fumed silica (e.g., CAB-O- SIL), colloidal silica, hydrophobic colloidal silica (e.g., AEROSIL R972), hydrophilic colloidal silica (e.g., AEROSIL 200 PHARMA), silica gel, precipitated silica, and the like.
  • the one or more glidant is generally present in the range of 0.1% to 5%, by weight of the pharmaceutical composition. In some embodiments, the one or more glidant is present in the range of 0.25% to 2%, by weight of the pharmaceutical composition.
  • Buffering agents that may be used in the pharmaceutical compositions of the present disclosure include, but are not limited to, triethylamine, meglumine, diethanolamine, ammonium acetate, arginine, lysine, histidine, a phosphate buffer (e.g., sodium phosphate tribasic, sodium phosphate dibasic, sodium phosphate monobasic, or o-phosphoric acid), sodium bicarbonate, a Britton- Robinson buffer, a Tris buffer (containing Tris(hydroxymethyl)-aminomethane), a HEPES buffer (containing N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid), acetate, a citrate buffer (e.g., citric acid, citric acid anhydrous, citrate monobasic, citrate dibasic, citrate tribasic, citrate salt), ascorbate, glycine, glutamate, lactate, malate, formate, sulfate, and mixture
  • pH-adjusting agents that may be used in the pharmaceutical compositions of the present disclosure include pharmaceutically acceptable acids or bases.
  • acids may include, but are not limited to, one or more inorganic mineral acids such as hydrochloric, hydrobromic, sulfuric, phosphoric, nitric, and the like; or one or more organic acids such as acetic, succinic, tartaric, ascorbic, citric, glutamic, benzoic, methanesulfonic, ethanesulfonic, trifluoroacetic, and the like.
  • the bases may be one or more inorganic bases or organic bases, including, but not limited to, alkaline carbonate, alkaline bicarbonate, alkaline earth metal carbonate, alkaline hydroxide, alkaline earth metal hydroxide, or amine.
  • the inorganic or organic base may be an alkaline hydroxide such as lithium hydroxide, potassium hydroxide, cesium hydroxide, sodium hydroxide, or the like; an alkaline carbonate such as calcium carbonate, sodium carbonate, or the like; or an alkaline bicarbonate such as sodium bicarbonate, or the like; the organic base may also be sodium acetate.
  • Surfactants that may be used in the pharmaceutical compositions of the present disclosure may include, but are not limited to, sodium lauryl sulfate, docusate sodium, dioctyl sodium sulfosuccinate, dioctyl sodium sulfonate, benzalkonium chloride, benzethonium chloride, lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil (e.g., polyoxyethylene hydrogenated castor oil 10, 50, or 60), glycerol monostearate, polysorbate (e.g., polysorbate 40, 60, 65, or 80), sucrose fatty acid ester, methyl cellulose, polyalcohols, and ethoxylated polyalcohols, thiols (e.g., mercaptans) and derivatives, poloxamers, polyethylene glycol-fatty acid esters (e.g., KOLLIPHOR RH40, KOLLIPHOR EL),
  • Antioxidants that may be used in the pharmaceutical compositions of the present disclosure include, but are not limited to, acetylcysteine, ascorbyl palmitate, BHA, BHT, monothioglycerol, potassium nitrate, sodium ascorbate, sodium formaldehyde sulfoxylate, sodium metabisulfite, sodium bisulfite, vitamin E or a derivative thereof, propyl gallate, EDTA (e.g., disodium edetate), DTPA, bismuth sodium triglycollamate, or a combination thereof.
  • acetylcysteine ascorbyl palmitate
  • BHA BHT
  • monothioglycerol potassium nitrate
  • sodium ascorbate sodium formaldehyde sulfoxylate
  • sodium metabisulfite sodium bisulfite
  • vitamin E or a derivative thereof propyl gallate
  • EDTA e.g., disodium edetate
  • DTPA bismut
  • Antioxidants may also comprise amino acids such as methionine, histidine, cysteine and those carrying a charged side chain, such as arginine, lysine, aspartic acid, and glutamic acid.
  • amino acids such as methionine, histidine, cysteine and those carrying a charged side chain, such as arginine, lysine, aspartic acid, and glutamic acid.
  • Any stereoisomer (e.g., 1-, d-, or a combination thereof) of any particular amino acid e.g., methionine, histidine, arginine, lysine, isoleucine, aspartic acid, tryptophan, threonine and combinations thereof
  • combinations of these stereoisomers may be present so long as the amino acid is present either in its free base form or its salt form.
  • a single excipient may provide more than one function.
  • microcrystalline cellulose when present can function as both a filler and a binder.
  • multifunctional excipients can be used in combination with other functional excipients.
  • microcrystalline cellulose may be used with other fillers and/or other binders.
  • compositions of the present disclosure may be in a dosage form appropriate for oral administration.
  • the pharmaceutical compositions may be in the form of granules, or may be prepared as granules as an intermediate step to forming another oral dosage form, such as tablets, sprinkles, or pellets.
  • the pharmaceutical compositions may be in a solid dosage form for oral administration, such as a capsule, tablet, sprinkle, or pellet.
  • compositions of the disclosure in the form of a tablet may be prepared using methods known in the art.
  • the nilotinib ASD and the one or more pharmaceutically acceptable additives may be blended to provide a tableting blend by hand or bag blending, or using a suitable device.
  • Suitable tableting blends may then be compressed into tablets having a target weight from 50 to 1000 mg using, for example, a manual tablet press or a conventional mechanical tablet press.
  • granules may be desirable to form granules as an intermediate step to forming a tableting blend.
  • Granules typically have improved flow, handling, blending, and compression properties relative to ungranulated materials.
  • the granules may be prepared from the ASD particles by processes known in the art, including wet granulation and dry granulation.
  • the granulation blend may comprise the ASD in an amount of 20% to 80%, or in an amount of 25% to 75%, by weight.
  • the granulation blend comprises 20%, or 25%, or 30%, or 35%, or 40%, or 45%, or 50%, or 55%, or 60%, or 65%, or 70%, or 75%, or 80% of the ASD, by weight.
  • the granulation blend accordingly would contain a relatively high proportion of the ASD; if a lower proportion of extra-granular excipients is employed, then the granulation blend can contain a relatively lower proportion of the ASD.
  • the granulation blend is formed by dry-blending granule components, and then the granulation blend is densified using a roller compactor which typically forms ribbons of material. The ribbons are then reduced in size by milling to form granules. Improved wetting, disintegrating, dispersing and dissolution properties is obtained by the inclusion of suitable excipients, as described above. After granulation, the granules can be included into a tableting blend and compressed into tablets.
  • the pharmaceutical compositions are in the form of a tablet.
  • immediate release pharmaceutical composition is a tablet, and wherein the tablet is prepared by a method comprising:
  • ASD amorphous solid dispersion
  • step (ii) adding the blend of step (i) into roller compaction, and forming granules
  • step (iii) adding disintegrant and lubricant to the granules of step (ii)
  • step (iv) compressing the blend of step (iii) into tablet
  • the tablet may comprise the ASD in an amount of 20% to 50% by weight of the tablet; one or more solubilizer (such as polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer) in an amount 20% to 40% by weight of the tablet; one or more fillers (such a mannitol and/or microcrystalline cellulose); one or more disin tegrants (such as croscarmellose sodium and crospovidone); one or more lubricants and/or glidants (such as hydrophobic colloidal silica and/or magnesium stearate); and one or more binders (such as crospovidone).
  • the tablets are further film coated.
  • the film may be a hydrophilic/hydrophobic polymer selected from the group consisting of hydroxypropyl cellulose, ethyl cellulose, PVA or combinations thereof.
  • the disclosure provides pharmaceutical compositions that are effectively bioequivalent to a suitable reference composition when administered to healthy human subjects in a fasted state, but at a lower molar dose of the active ingredient as compared to the reference composition.
  • the present invention provides a method of increasing bioavailability by administering the composition or the pharmaceutical composition of the invention, respectively, to an animal or to a patient, wherein the increased bioavailability is determined by comparing the Cmax value or the AUC value of the composition or the pharmaceutical composition of the invention with the composition disclosed in the present invention.
  • the method increases bioavailability of a drug in administered animal or patient by least 1.3 fold, preferably at least 1.5 fold, even more preferably by at least two fold, over marketed TASIGNA® hard-gelatin capsule.
  • the pharmaceutical composition when administered to a human subject in fed state provides a Cmax value of nilotinib not more than 30%, preferably not more than 20%, preferably not more than 10%, preferably not more than 5% and more preferably not more than 1% as compared to the Cmax value of nilotinib resulting from administration of the pharmaceutical composition to the human subject in fasted state.
  • the pharmaceutical composition when administered to a human subject in fed state provides an AUC value not more than 45%, preferably not more than 40%, preferably not more than 30%, preferably not more than 10%, and more preferably not more than 5% as compared to the AUC value resulting from administration of the pharmaceutical composition to the human subject in fasted state.
  • Bioavailability can be measured by skilled artisan by conventional methods. For example, tablets, capsules, liquids, powders, etc., are given orally to humans or animals and blood levels are measured.
  • AUCo-t such as AUCo-24h or AUCo-inf
  • Cmax in the subject
  • fraction of the dosage may mean that the dose of nilotinib in the ASD or pharmaceutical composition of the present disclosure may be 80% less, or 75% less, or 70% less, or 65% less, or 60% less, or 55% less, or 50% less, or 45% less, or 40% less, or 35% less, or 30% less, or 25% less, or 20% less, as compared to the labeled dosage of the immediate- release nilotinib formulation.
  • the dose of nilotinib in the ASD or pharmaceutical composition of the present disclosure is at least 80% less, or 75% less, or 70% less, or 65% less, or 60% less, or 55% less, or 50% less, as compared to the labeled dosage of the immediate-release crystalline nilotinib formulation.
  • a pharmaceutical composition of the present disclosure containing approximately 100 mg nilotinib provide a pharmacokinetic profile that is comparable to the pharmacokinetic profile obtained by orally administering an immediate- release crystalline nilotinib formulation labeled to contain 150 mg of nilotinib (such as 150 mg TASIGNA®).
  • a pharmaceutical composition of the present disclosure containing approximately 135 mg nilotinib provide a pharmacokinetic profile that is comparable to the pharmacokinetic profile obtained by orally administering an immediate- release crystalline nilotinib formulation labeled to contain 200 mg of nilotinib (such as 200 mg TASIGNA®).
  • a pharmaceutical composition of the present disclosure containing approximately 95 mg nilotinib provide a pharmacokinetic profile that is comparable to the pharmacokinetic profile obtained by orally administering an immediate- release crystalline nilotinib formulation labeled to contain 200 mg of nilotinib (such as 200 mg TASIGNA®).
  • Overexposure to nilotinib is associated with the risk of QT prolongation discussed above, which is currently the subject of a “black box warning” on the TASIGNA® label.
  • the risk of overexposure affects the entire patient population treated with nilotinib.
  • the formulations of the disclosure may limit risk associated with an undesirably high Cmax.
  • Some embodiments relate to a use of a nilotinib ASD or pharmaceutical composition of the present disclosure in the manufacture of a medicament for treating a proliferative disorder such as cancer.
  • a therapeutically effective amount may be from 50 mg/m 2 to 250 mg/m 2 of nilotinib, or from 50 mg/m 2 to 150 mg/m 2 of nilotinib, or from 60 to 120 mg/m 2 of nilotinib.
  • food effect broadly refers to all aspects of interactions of food on drug dissolution, absorption, distribution, metabolism and elimination.
  • the implications of food effect include changes in bioavailability, rate of on-set, duration of therapeutic effect and incidence and seriousness of side effects.
  • the magnitude of a food effect is generally greatest when the drug product is administered shortly after a meal is ingested.
  • TASIGNA® An example of a drug product exhibiting a food effect is TASIGNA®, which can produce an increase of AUC and Cmax by 82% and 112%, respectively, when orally taken 30 minutes after a high-fat meal as compared to levels obtained under fasting conditions.
  • Fasted and fed studies may be single-dose studies or steady-state studies, as appropriate.
  • pooled data from a suitable number of subjects an absence of food effect is indicated when the 90% confidence interval for the ratio of population geometric means between fed and fasted administrations, based on log- transformed data, is contained in the equivalence limits of 80% to 125% for AUCo-inf (or AUCo-t when appropriate) and Cmax.
  • “without a food effect” means that the relative difference is not substantially large, e.g., less than 20%, or less than 15%, or less than 10%, for AUC (which can be, for example, AUCo-24h, AUCo-iast or AUCo-inf) and/or Cmax, for nilotinib when the ASD or pharmaceutical composition of the present disclosure is administered orally, concomitantly with food or in a fed state, as compared to the measured value for the same parameter when the same ASD or pharmaceutical composition is administered in a fasted state.
  • AUC which can be, for example, AUCo-24h, AUCo-iast or AUCo-inf
  • Cmax for nilotinib
  • “without regard to consumption of food” means that no consideration has to be made whether the ASD or pharmaceutical composition of the present disclosure is being administered to the subject or patient concomitantly with food, or whether the patient or subject is in a fed state or fasted state.
  • administration of the ASD or pharmaceutical composition to a subject in a fed state provides an exposure of nilotinib that is similar to the exposure resulting from administration of the pharmaceutical composition to the subject in a fasted state.
  • Exposure may be expressed as AUCo-i2h, AUCo-24h, AUCo-iast, or AUCo-inf, for example; exposure can be for an individual subject, or a geometric mean from a number of subjects.
  • pharmaceutical composition administration to a subject in a fed state provides a plasma Cmax of nilotinib that is similar to the plasma Cmax resulting from administration of pharmaceutical composition to the subject in a fasted state.
  • Plasma Cmax can be for an individual subject, or a geometric mean from a number of subjects.
  • similar means a relative difference in the plasma exposure of nilotinib between the fed state and the fasted state of less than 25%, or less than 20%, or less than 15%, or less than 10%, or less than 5%.
  • Example-1 Amorphous solid dispersion of nilotinib
  • Manufacturing process i. preparing a solution comprising nilotinib and hypromellose pthalate, using dimethylacetamide ii. mixing the solution obtained in step (i) to cooled acidified water (pH 1.0-5.0) to precipitate out both the drug and the polymer; and iii. filtering and washing the solid mass obtained in step (ii) with fresh antisolvent and water, and dried to obtain amorphous solid dispersion of the present invention.
  • Example-2 Amorphous solid dispersion of nilotinib
  • Example 3 Tablet compositions of Nilotinib ASD from Example 1 [T2] and Example 2 [Tl]
  • Nilotinib ASD, soluplus, and a portion of mannitol, croscarmellose sodium, crospovidone, colloidal silicon dioxide and magnesium stearate are sifted and mixed;
  • step ( 1 ) The granulation blend obtained in step ( 1 ) was roller-compacted and granulated;
  • Nilotinib ASD granules obtained in step (3) were mixed with remaing portion of crospovidone, colloidal silicon dioxide and magnesium stearate; and the tabletting blend obtained was then compressed into tablets.
  • Nilotinib tablets T1 & T2 prepared according to Example 3 were evaluated for in vitro dissolution, against TASIGNA® 200mg tablets (Reference Formualtion).
  • the dissolution was performed using two stage dissolution procedure where acid media was transferred to base media inorder to mimic the invivo condition and to check the rate of precipitation inhibition in alkline media.
  • SGF Simulated Gastric Fluid
  • FaSSIF Fasted State Stimulated Intestinal Fluid
  • the total volume of FaSSIF media becomes 750mE after addition of acid media (250mE 0.01N HC1 + 500mE pH 6.8 Phosphate buffer). The sampling was done simultaneously at different time points while addition of acid media and continued dissolution up to 240mins.
  • T1 and T2 furnishes a better dissolution than that of the Reference formulation (TASIGNA® 200mg tablets). Further T1 formulation has shown better results as compared to T2 formulations. It is also clear that the Test formulation does not undergo precipitation in buffer media contrary to that of the Reference formulation. Based on the dissolution results as shown in Example 4, the T1 and T2 formulations were further tested for in-vivo PK testing in human subjects against TASIGNA® 200mg tablets (Reference Formulation).
  • Example 5 Comparative in-vivo Pharmacokinetic (PK) study in human subjects
  • PK study was conducted. This study is an open label, randomized, three-treatment, Four-period, Four Sequence, Single dose, crossover, oral bioavailability study of nilotinib Tablets 135mg (135mg x 2 tablets) of Dr. Reddy’s Eaboratories Limited, India comparing with that of reference formulation TASIGNA® (Nilotinib) capsules 200mg (200 mg x 2 capsule) of Novartis Biosciences SA Brazilian Industry in normal, healthy, adult, human subjects under fasting and fed conditions.
  • TASIGNA® Nelotinib
  • Table 6 Statistical Summary for nilotinib tablets 135 mg Fed Study (TIFe/TIFa)
  • PK in-vivo Pharmacokinetic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique à libération immédiate comprenant des dispersions solides amorphes de l'inhibiteur de protéine kinase, du nilotinib ou un sel pharmaceutiquement acceptable de celui-ci, et des compositions pharmaceutiques les comprenant. Plus particulièrement, la présente invention concerne des compositions pharmaceutiques améliorées de nilotinib, ou d'un sel pharmaceutiquement acceptable de celui-ci, qui peuvent être administrées sans tenir compte de la consommation d'aliments et qui peuvent être administrées à une dose significativement inférieure par rapport à une formulation de nilotinib à libération immédiate disponible dans le commerce, tout en fournissant un effet thérapeutique comparable. L'invention concerne également un procédé de préparation desdites compositions.
PCT/IN2024/050382 2023-04-12 2024-04-12 Composition pharmaceutique du nilotinib Pending WO2024214120A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202341026974 2023-04-12
IN202341026974 2023-04-12

Publications (1)

Publication Number Publication Date
WO2024214120A1 true WO2024214120A1 (fr) 2024-10-17

Family

ID=93059058

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2024/050382 Pending WO2024214120A1 (fr) 2023-04-12 2024-04-12 Composition pharmaceutique du nilotinib

Country Status (1)

Country Link
WO (1) WO2024214120A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020055838A (ja) * 2012-01-13 2020-04-09 エックススプレイ ファーマ パブリーク・アクチエボラグＸＳｐｒａｙ Ｐｈａｒｍａ ＡＢ（ｐｕｂｌ） 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分を含む安定な非晶質のハイブリッドナノ粒子を製造する方法
WO2021222739A1 (fr) * 2020-04-30 2021-11-04 Nanocopoeia, Llc Comprimé à désintégration orale comprenant une dispersion solide amorphe de nilotinib

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020055838A (ja) * 2012-01-13 2020-04-09 エックススプレイ ファーマ パブリーク・アクチエボラグＸＳｐｒａｙ Ｐｈａｒｍａ ＡＢ（ｐｕｂｌ） 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分を含む安定な非晶質のハイブリッドナノ粒子を製造する方法
WO2021222739A1 (fr) * 2020-04-30 2021-11-04 Nanocopoeia, Llc Comprimé à désintégration orale comprenant une dispersion solide amorphe de nilotinib

Similar Documents

Publication Publication Date Title
ES2993251T3 (en) Pharmaceutical compositions of nilotinib
US10561654B2 (en) Pharmaceutical formulations of (S)-methyl(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
US11679105B1 (en) Pharmaceutical compositions of cabozantinib
US12433891B2 (en) Amorphous solid dispersions of dasatinib and uses thereof
US20220280500A1 (en) Pharmaceutical compositions of cabozantinib
US20220387418A1 (en) Pharmaceutical compositions of cabozantinib
JP7378393B2 (ja) 改善された薬物製剤
KR102707060B1 (ko) 안정성 및 생체이용율이 개선된 올라파립 고체 분산체 조성물
WO2024214120A1 (fr) Composition pharmaceutique du nilotinib
WO2013147135A1 (fr) Composition pharmaceutique à libération contrôlée
WO2024184927A1 (fr) Composition orale solide d'olaparib et de ses sels

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24788377

Country of ref document: EP

Kind code of ref document: A1

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025022035

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: DE